Thyminalkylamine
| Code | Size | Price |
|---|
| TAR-T34865-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Thyminalkylamine is a biochemical.
CAS:
7264-21-3
Formula:
C9H13Cl2N3O2
Molecular Weight:
266.12
Purity:
0.98
SMILES:
ClCCN(CCCl)Cc1c[nH]c(=O)[nH]c1=O
References
Bohunick? E, Koza I, Kuzela S, Krempask? V, Ujh?zy V. Immunosuppression with thyminalkylamine (Ypenyl Spofa): effect on antibody plaque-forming spleen cells. Neoplasma. 1972;19(5):499-505. PubMed PMID: 4404912.
DVORAK O, ELIS J, JELINEK J, KAFKA V, MUSIL J, SCHUBERT J. COMPARISON OF THYMINALKYLAMINE AND ENDOXAN EFFECT ON ADVANCED GYNECOLOGICAL CARCINOMAS IN A CONTROLLED CLINICAL TRIAL. Neoplasma. 1965;12:87-91. PubMed PMID: 14278335.
Dvor?k O, Elis J, Perl?k F, Kv?calov? M, Jandov? A, Skoda V, Kafka V. A controlled clinical trial with the cytostatic agent thyminalkylamine and its fluorinated derivative on advanced ovarian tumours. Neoplasma. 1971;18(4):365-9. PubMed PMID: 5568931.